Search Results
Your search for can matches 13815 pages
Showing 2101 - 2150Being on the Other Side: An Oncologist’s Perspective on Grieving
As an oncologist, I had cared for patients facing grave illness and death. I imagined the loss of loved ones and expected grief to be an unbearable sadness, most poignant in the earliest days and lessening with time. I somehow expected that counseling people who grieved would make me more prepared. ...
Expert Point of View: Urvi A. Shah, MD
Urvi A. Shah, MD, Assistant Attending at Memorial Sloan Kettering Cancer Center and Assistant Professor at Weill Cornell Medicine, New York, moderated the session where the MagnetisMM trial updates1,2 were reported and was interviewed by The ASCO Post. Elranatamab vs Teclistamab Dr. Shah noted...
Cardiovascular Events Before and After Initiation of Immune Checkpoint Inhibitor Therapy for Cancer
In a study reported in JACC: CardioOncology, Lavanya Kondapalli, MD, of the University of Colorado School of Medicine, Aurora, and colleagues found that cardiovascular events common in the general population were observed both prior to and after the initiation of immune checkpoint inhibitor therapy ...
Study Explores the Addition of First-Line Atezolizumab in BRAF V600–Mutant Advanced Melanoma
As reported in The Lancet Oncology by Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Pascale, Naples, and colleagues, the second interim overall survival analysis of the phase III IMspire150 trial has shown a numeric but...
FDA Oncology Center of Excellence Seeks Applications for New Research Funding Opportunities
OCE Insights is an occasional column developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Julie A. Schneider, PhD, Associate Director for Research Strategy and Partnerships, OCE; Jennifer J. Gao, MD,...
New Study Evaluates Online Colorectal Cancer Risk Calculators
Many individuals considering screening for colorectal cancer may want information on their personal risk when making decisions about screening—such as whether to select an at-home stool-based test or colonoscopy. Investigators evaluated five online colorectal cancer risk calculators to determine...
Trends in Stage, Treatment, and Outcomes in Rectal Adenocarcinoma in the United States: 2004 to 2019
In a retrospective, observational case series study reported in JAMA Oncology, Emile et al identified changes in the stage at diagnosis, treatments, and outcomes in U.S. patients with rectal adenocarcinoma diagnosed between 2004 and 2019. Study Details The study used National Cancer Database data...
NAPOLI-3: First-Line NALIRIFOX Regimen Improves Overall Survival in Metastatic Pancreatic Cancer
In the phase III NAPOLI-3 trial in previously untreated patients with metastatic pancreatic cancer, the NALIRIFOX regimen significantly improved overall survival and progression-free survival over nab-paclitaxel plus gemcitabine. NALIRIFOX contains liposomal irinotecan, fluorouracil, leucovorin,...
ASCO Guideline Offers Recommendations on Prescribing Opioids to Patients With Cancer
A new ASCO guideline on opioids in managing pain from cancer or cancer treatment in adults provides recommendations on administering them in the midst of interventions to address the public health crisis from their misuse and related deaths across the country.1 “ASCO took wonderful leadership in...
Expert Point of View: Solange Peters, MD, PhD
The formal discussant of ARC-7 was Solange Peters, MD, PhD, Chair of Medical Oncology, Centre D’Oncologie Chuv, Lausanne University Hospital, Switzerland, and President of the European Society for Medical Oncology. Dr. Peters described how TIGIT (T-cell immunoglobulin and ITIM domain) plays a role ...
Anti-TIGIT Antibody May Boost the Benefit of Immunotherapy in Stage IV Lung Cancer
In a phase II study of stage IV non–small cell lung cancer (NSCLC), domvanalimab, a novel antibody that blocks T-cell immunoglobulin and ITIM domain (TIGIT), when added to anti–PD-1 zimberelimab immunotherapy resulted in improved response rates and progression-free survival compared with...
Olutasidenib for Relapsed or Refractory Acute Myeloid Leukemia With a Susceptible IDH1 Mutation
On December 1, 2022, the IDH1 inhibitor olutasidenib was approved for the treatment of adults with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation, as detected by a U.S. Food and Drug Administration (FDA)-approved test.1 The FDA simultaneously approved the Abbott...
Expert Point of View: Jane N. Winter, MD and Catherine Bollard, MBChB, MD
Offering their thoughts on the study by Williams et al from the St. Jude Lifetime Cohort were Jane N. Winter, MD, Immediate Past President of the American Society of Hematology (ASH), and Catherine Bollard, MBChB, MD. Both moderated press briefings where the results were presented or discussed....
Many Survivors of Childhood Hodgkin Lymphoma Show Signs of Neurocognitive Impairment
Long-term follow-up of survivors of childhood Hodgkin lymphoma from the St. Jude Lifetime Cohort showed signs of “epigenetic accelerated aging,” and many of these survivors had signs of neurocognitive impairment by their late 30s, researchers reported at the 2022 American Society of Hematology...
Expert Point of View: Julio Chavez, MD
Julio Chavez, MD, a hematologist at Moffitt Cancer Center, Tampa, Florida, commented on the updated results from the MAGNOLIA trial. “MAGNOLIA was a phase II trial that included patients with marginal zone lymphoma after one or more prior lines of therapy. At the ASH meeting, we heard updated...
Subset of Patients With Advanced Gastric/GEJ Cancer May Benefit From CLDN18.2-Targeted Drug Zolbetuximab: SPOTLIGHT Study
Initial data from the global phase III SPOTLIGHT trial could herald the use of a new targeted agent for a subset of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. First-line treatment with zolbetuximab, which targets the transmembrane protein claudin 18.2...
Is Zanubrutinib Poised to Become a New Standard of Care in Relapsed or Refractory CLL and SLL?
The next-generation Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib demonstrated superior progression-free survival compared with ibrutinib, with an improved cardiac safety profile, in the first head-to-head comparison between these two BTK inhibitors in relapsed or refractory chronic...
Expert Point of View: Ajay K. Nooka, MD, MPH
Insights on findings from the phase II MonumenTAL-1 trial1 were offered by Ajay K. Nooka, MD, MPH, Professor in the Department of Hematology and Medical Oncology, and Medical Director of the Winship Data and Technology Applications Shared Resource, Winship Cancer Institute, Emory University School ...
Expert Point of View: Virginia Kaklamani, MD
Breast medical oncologist Virginia Kaklamani, MD, Professor of Medicine, UT Health San Antonio, MD Anderson Cancer Center, believes the results of the POSITIVE trial will help patients with breast cancer make decisions. “The trial is important because it helps us give advice to younger patients,”...
Can Younger Women With Hormone Receptor–Positive Breast Cancer Safely Pause Endocrine Therapy to Pursue Pregnancy?
Preserving fertility is a driving concern for many young women with breast cancer. Many of these women have hormone receptor–positive breast cancer and are treated with adjuvant endocrine therapy for 5 to 10 years, which is known to compromise fertility. Younger women who may want to take a break...
Expert Point of View: Carlos L. Arteaga, MD and William Sikov, MD
“There is a clear suggestion from SERENA-2 that camizestrant might be a better treatment than fulvestrant,” said press briefing moderator Carlos L. Arteaga, MD, Director of the Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs at UT Southwestern Medical Center, Dallas. “As ...
Expert Point of View: Jason Aboudi Mouabbi, MD
“These results [from the TRIO-US B-12 TALENT trial] are exciting and impressive in HER2-low, hormone receptor–positive patients. The authors were testing the waters and got a positive signal,” said Jason Aboudi Mouabbi, MD, a medical oncologist at MD Anderson Cancer Center, Houston. “The beauty of ...
Neoadjuvant T-DXd Demonstrates Activity in Phase II Study of Patients With HER2-Low Breast Cancer
A pilot study provides a signal that the novel HER2 antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd), is active in the neoadjuvant setting in patients with HER2-low breast cancer. Overall response rates were 75% with T-DXd alone and 63% when T-DXd was combined with endocrine therapy...
Addressing the Continued Existence of Racial Inequities in Cancer Care
The opportunity to write this commentary on cancer disparities comes at a sorrowful time for me. Despite practicing as a surgical oncologist for more than 20 years and understanding the unequal burden that cancer visits on the Black community, I was woefully unprepared for the premature death of my ...
Study Shows Activity of Talquetamab in Highly Refractory Multiple Myeloma
In the phase I/II MonumenTAL-1 trial, the novel bispecific antibody talquetamab produced responses in more than 70% of heavily pretreated patients with multiple myeloma.1 Of note, the safety profile confirmed results of the phase I portion of the study (recently published in TheNew England Journal...
Ensuring a More Diverse, Equitable, and Inclusive Workforce Within the SWOG Cancer Research Network
For more than 2 decades, Don S. Dizon, MD, FACP, FASCO, has devoted his medical career to the care of women’s cancers and the sexual health of cancer survivors of all genders and sexual identities. Early in his career, Dr. Dizon founded the Center for Sexuality, Intimacy, and Fertility at Women...
Uterine Cancer Now Covered by WTC Health Program
Researchers at Rutgers, The State University of New Jersey, and caregivers have helped secure medical coverage and financial compensation for individuals who were exposed to Ground Zero and consequently developed uterine cancer, including endometrial cancer—according to a new, final rule added to...
Study Suggests Ibrutinib May Obviate Need for Autologous Stem Cell Transplantation in Some Younger Patients With Mantle Cell Lymphoma
Although longer follow-up is needed, the results of the three-arm randomized TRIANGLE study suggest that the tyrosine kinase inhibitor ibrutinib may replace autologous stem cell transplantation (ASCT) after chemoimmunotherapy in younger patients with previously untreated mantle cell lymphoma (MCL). ...
Study Suggests Ibrutinib May Obviate Need for ASCT in Some Younger Patients With Mantle Cell Lymphoma
Although longer follow-up is needed, the results of the three-arm randomized TRIANGLE study suggest that the tyrosine kinase inhibitor ibrutinib may replace autologous stem cell transplantation (ASCT) after chemoimmunotherapy in younger patients with previously untreated mantle cell lymphoma (MCL). ...
Reminders Based on Machine-Learning Algorithms May Improve End-of-Life Care for Patients With Cancer
Electronic nudges delivered to health-care clinicians based on a machine-learning algorithm capable of predicting mortality risk quadrupled rates of conversations with patients about their end-of-life care preferences, according to a new study published by Manz et al in JAMA Oncology. The study...
Molecular Tumor Board Offers Assistance That May Boost Effectiveness of Precision Oncology
The field of precision oncology has become so complex that even experienced oncologists can find it challenging to decipher the molecular test results of tumor tissue and navigate treatment options for patients. Investigators revealed that a new program may aid gastrointestinal cancer physicians in ...
Can Women With Two or Three Ipsilateral Breast Cancer Sites Safely Undergo Breast-Conserving Therapy?
Many women with two or three cancerous lesions in the breast can safely undergo lumpectomy followed by radiation therapy, according to the results of a prospective phase II trial reported at the 2022 San Antonio Breast Cancer Symposium.1 In this study, local recurrence rates after breast-conserving ...
Novel AI Tool May Predict Risk of Lung Cancer Using Low-Dose CT Scan Data
Researchers have developed and tested an artificial intelligence (AI) tool known as Sybil, which may accurately predict the risk of lung cancer for individuals with or without a significant smoking history using data from low-dose chest computed tomography (CT) scans, according to a new study...
Expert Point of View: Joseph C. Alvarnas, MD
“Pediatric acute lymphoblastic leukemia (ALL) is the paradigmatic success story in hematology,” said Joseph C. Alvarnas, MD, Professor in the Department of Hematology and Hematopoietic Cell Transplant, Vice President of Government Affairs, and Chief Clinical Advisor for AccessHope at City of Hope...
Blinatumomab Improves Survival in MRD-Negative, B-Cell ALL
The standard of care could be changing for adults with newly diagnosed BCR-ABL–negative B-lineage acute lymphoblastic leukemia (ALL) who achieve measurable residual disease (MRD) negativity after induction chemotherapy. In the phase III E1910 trial by the ECOG-ACRIN Cancer Research Group, an...
Ruxolitinib Demonstrates Clinical Activity in a Phase II Trial of Chronic Myelomonocytic Leukemia
In a phase II trial, treatment with the JAK2 inhibitor ruxolitinib resulted in clinical activity in two-thirds of patients with chronic myelomonocytic leukemia (CMML) with splenomegaly or an otherwise high disease symptom burden. The magnitude of symptomatic benefit was similar to that observed in...
Experts Publish Consensus Statement on Classification System for Pathology and Diagnosis of Melanocytic Lesions
In recognition of continuing issues with the process of melanocytic pathology assessments, an expert panel of three dermatopathologists—with assistance from an expert team of researchers—has developed and now revised the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis schema...
New Scoring System Measures Inflammation Levels, May Improve Risk Stratification in AML
Researchers have discovered that severe inflammation may weaken the body’s ability to kill cancerous blood cells in patients with acute myeloid leukemia (AML), according to a new study published by Lasry et al in Nature Cancer. With bone marrow samples from 20 adults and 22 children with AML, the...
Study Finds Posoleucel Demonstrated Antiviral Efficacy and Safety Against Viral Infections Following Allogeneic Stem Cell Transplantation
Studies show that viral infections are common causes of morbidity and mortality in patients undergoing hematopoietic stem cell transplantation and can induce a profound immunocompromised state in some patients that may last up to 24 months or longer posttransplant. In an open-label, single-arm,...
Cancer Survival in Africa, Central and South America, and Asia: SURVCAN-3 Study
In the population-based SURVCAN-3 study reported in The Lancet Oncology, Soerjomataram et al identified cancer survival rates in 32 countries in Africa, Central and South America, and Asia. They found that disparities for many cancer types reflect the standing of countries according to the Human...
Fewer Cases of Melanoma Found Among Individuals Taking Vitamin D Supplements
Fewer cases of melanoma were observed among individuals who regularly took vitamin D supplements than among those who did not take the supplements, according to a new study published by Kanasuo et al in Melanoma Research. Researchers also found that individuals taking vitamin D supplements...
Study Identifies Potential Molecular Differences Between Primary Breast Cancer and Its Metastases
Researchers have identified unique molecular features responsible for the development and progression of metastatic breast cancer, according to a novel study published by Garcia-Recio et al in Nature Cancer. They discovered that one of the key features involves changes in the immune system that are ...
Study Investigates Burden of Cervical Cancer Among Patients Aged 65 and Older
Researchers discovered that a significant number of patients aged 65 years and older may be facing late-stage cervical cancer diagnoses and disease-related mortality—despite U.S. Centers for Disease Control and Prevention (CDC) guidelines recommending that most patients stop screening for cervical...
Novel Therapy Afamitresgene Autoleucel Shows Early Potential for Antitumor Activity
The adoptive T-cell receptor therapy afamitresgene autoleucel—which targets the MAGE-A4 cancer antigen—achieved clinically significant results for patients with multiple solid tumor types in a phase I clinical trial, according to a novel study published by Hong et al in Nature Medicine. Initial...
Addition of Apalutamide May Slow Progression of Early-Stage Prostate Cancer During Active Surveillance
For patients with early-stage prostate cancer being managed by active surveillance, adding the hormonal agent apalutamide may lower the rate of positive biopsies during follow-up, suggest findings from a preliminary clinical trial published by Schweizer et al in The Journal of Urology. "In our...
Immune System B Cells May Help to Predict Treatment Response Among Patients With HER2-Positive Breast Cancer
Researchers have found that measuring the activation of immune system B cells may be more effective than measuring the activation of either T cells or tumor-infiltrating lymphocytes (TILs) in predicting whether patients with HER2-positive breast cancer will respond to treatment. These findings were ...
New AI-Based Biomarker May Help Predict Immunotherapy Response for Patients With NSCLC
Researchers have discovered a new artificial intelligence (AI)-derived biomarker that uses routine imaging scans to help predict which patients with non–small cell lung cancer (NSCLC) will respond to immunotherapy, according to a novel study published by Alilou et al in Science Advances. The...
Prostate Cancer Screening Among Primary Care Providers
Investigators recently examined prostate cancer screening among primary care providers and found that screening tests were frequently used—even when they provide little value to patients, according to a new study published by Gillette et al in the Journal of the American Board of Family Medicine....
FoundationOne Liquid CDx Receives FDA Approval as a Companion Diagnostic for Entrectinib
On January 4, the U.S. Food and Drug Administration (FDA) approved FoundationOne Liquid CDx to be used as a companion diagnostic to identify patients with ROS1-positive non–small cell lung cancer (NSCLC) or NTRK fusion–positive solid tumors who do not have a tissue sample available and may be...
Mitomycin Gel for Upper Tract Urothelial Cancers: Postmarket Analysis
Researchers have performed the first postmarkert analysis of a novel delivery system of mitomycin—a gel formation, also known as UGN-101—to treat upper tract urothelial cancers, according to a novel study published by Woldu et al in Urologic Oncology. Their findings showcase how the treatment is...
